3 ASX healthcare shares up 10% to 22% on news

These healthcare shares are catching the eye on Wednesday. But why?

| More on:
A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There have been some big movers in the healthcare sector on Wednesday.

Here's why these ASX healthcare shares are up over 10% today:

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up over 13% to $3.12. Investors have been buying this ASX healthcare share today after it released a quarterly update. Mayne Pharma reported an improved performance during the quarter, with all segments delivering a positive contribution margin. This led to quarterly sales of $92.3 million, a gross margin of 58%, and a cash EBITDA loss of $1.7 million. As a comparison, in the fourth quarter, Mayne Pharma reported sales of $68.2 million, a gross margin of 43%, and a cash EBITDA loss of $19.5 million.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm share price is up 22% to 77 cents. This follows the release of an update on the biopharmaceutical company's injectable pentosan polysulfate sodium (iPPS) treatment. The release notes that iPPS increases cartilage thickness at six months in participants with knee osteoarthritis compared to cartilage loss in placebo group. Management believes the results indicate a treatment effect on osteoarthritis beyond the relief of symptoms and "supports iPPS as a blockbuster opportunity."

Starpharma Holdings Ltd (ASX: SPL)

The Starpharma share price is up 11% to 5 cents. This morning, this ASX healthcare share reported that its DEP cabazitaxel phase two clinical trial met its objectives. Endpoints demonstrated positive antitumour efficacy in multiple cancers and confirmed the product's favourable safety and tolerability profile. Management believes the promising efficacy results in advanced prostate, ovarian, and gastro-oesophageal cancers create a significant market opportunity for DEP cabazitaxel.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Starpharma. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would ticks all of my boxes for a great investment.

Read more »

Five arrows hit the bullseye of five round targets lined up in a row, with a blue sky in the background.
Healthcare Shares

When might CSL shares hit the $300-mark again?

CSL is on track for $300, if one broker is to be believed.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

2 ASX healthcare shares I think are overdue for a big rally

I think these early stage drug companies could have a barnstorming 2024.

Read more »

Businesswoman whispering in male colleague's ear as he looks surprised
Share Gainers

Up 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?

Why are these pharmaceutical shares turning heads at the moment? The Elvest team explains.

Read more »

a woman puts a pen to her mouth as she smiles slightly while checking an old book style diary/calendar.
Healthcare Shares

Dates that could move the NIB share price in 2024

NIB shares investors, get out your 2024 diaries...

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 healthcare stock is surging 8% on record sales

This medical device company's sales growth was strong in November.

Read more »

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »